Previous 10 | Next 10 |
What do a leading fintech player, a mobile communications company, and a key supplier to the bioprocessing industry all have in common? The businesses in question are PayPal (NASDAQ: PYPL) , Digital Turbine (NASDAQ: APPS) , and Repligen (NASDAQ: RGEN) , and t...
As Q1 earnings season approaches, the consensus is for 28% bottom-line growth, which would be the best showing since Q3 2018.In the last quarter, "the immediate market reactions were mixed for positive surprises, while negative surprises were punished," Citi analysts write in a note.For Q1, t...
WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 23-24. ...
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chi...
Image source: The Motley Fool. Repligen Corp (NASDAQ: RGEN) Q4 2020 Earnings Call Feb 24, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Repligen Corp (RGEN) Q4 2020 Earnings Call Transcript
Repligen Corporation (RGEN) Q4 2020 Earnings Conference Call February 24, 2021 08:30 A.M. ET Company Participants Sondra Newman - Global Head of IR Tony J. Hunt - President and CEO Jon K. Snodgres - CFO Conference Call Participants Dan Arias - Stifel Unidentified Analyst - J.P. Morgan Paul Kn...
Repligen (RGEN): Q4 Non-GAAP EPS of $0.52 beats by $0.21; GAAP EPS of $0.36 beats by $0.19.Revenue of $108.64M (+56.4% Y/Y) beats by $14.7M.FISCAL YEAR 2021 GUIDANCE: Total revenue is expected to be in the range of $500-$525 million ($459.5M consensus), reflecting overall revenue growth...
Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth Organic revenue growth was 47% for the fourth quarter and 29% for the year 2020 WALTHAM, Mass., Feb. 24, 2021 ...
[[AVA]], [[BHC]], [[CLH]], [[CQP]], [[CSPR]], [[DEA]], [[ELAN]], [[ENBL]], [[ETR]], [[EV]], [[EXC]], [[FDP]], [[GCP]], [[HFC]], [[HZNP]], [[IBP]], [[IONS]], [[IRM]], [[ITRI]], [[KOP]], [[LIVN]], [[LNG]], [[LOW]], [[NEO]], [[ODP]], [[OMI]], [[OSTK]], [[PGTI]], [[PLAB]], [[PNW]], [[PSN]], [[RGE...
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26....
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...